Novo Nordisk just got a big win from the FDA, and it could change the weight-loss medicine industry again. Novo has a new weapon in its obesity portfolio with the once-daily Wegovy tablet, which is the first oral GLP-1 medication approved in the U.S. for weight loss. This comes at a time when ... Read more
Thestreet - Dec 28
The approval of Novo Nordisk's (NYSE:NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to choose one specific company.• What should traders watch with XLV?Broad funds like the Health Care Sel... Read more
Benzinga - Dec 23
Novo Nordisk A/S (NYSE:NVO) on Thursday submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema.The application covers CagriSema for use with a reduced-calorie diet and increased physical activity to treat obesity or overweight in the presen... Read more
Benzinga - Dec 18
The trials showed an effect on Alzheimer's biomarkers, though Novo did not specify which ones. Read more
The Hill - Nov 25
Novo Nordisk A/S (NYSE:NVO) shouldn't be trading like a meme stock — not when it's sitting on deep-value fundamentals, a GLP-1 fortress, and a pipeline pivot that could flip 2026 from bruised to breakout. Yet here we are: a 69% reset, sentiment in shambles, and a business that looks nothing like ... Read more
Benzinga - Nov 25
Novo Nordisk A/S (NYSE:NVO) stock fell on Monday after the company released topline results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease.The trials did not confirm the superiority of semaglutide versus placebo in the reduction ... Read more
Benzinga - Nov 25
Seamus Fernandez, Guggenheim biotech analyst, joins 'Power Lunch' to discuss Novo Nordisk's latest earnings results, if there's a clear winner in the GLP-1 space and much more. Read more
Cnbc - Nov 24
Evan Seigerman, BMO head of health care research, joins 'The Exchange' to discuss the gap between Novo Nordisk and Eli Lilly, the valuation gap between the stocks and much more. Read more
Cnbc - Nov 24
On Monday, Novo Nordisk announced a discount on its popular drugs for diabetes and obesity, Ozempic and Wegovy, cutting prices for the lowest doses to $199 when patients pay cash... Read more
Stat - Nov 18
In the current market session, Novo Nordisk Inc. (NYSE:NVO) price is at $48.56, after a 0.62% spike. However, over the past month, the stock fell by 11.35%, and in the past year, by 52.68%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is... Read more
Biztoc - Nov 17
